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Disease Management Guideline for Germany were identiﬁed.
The percentages of patients who had a switch in medications
were determined. In sub-analyses patients who were new to their
therapy and patients with concomitant (add on) medications
were also assessed. RESULTS: Compared with patients who
received the FSC, those receiving LABA+ICS were more likely to
have a switch in medication (35% versus 26%) and to use add
on medications (54% versus 35%). The highest proportion of
adequately adherent (°Y´70%) patients was among those switch-
ing between medications. About 64% of the FSC cohort showed
good adherence with an average MPR of 72%. In contrast only
15% of the patients using LABA+ICS were adequately adherent
with an average MPR of 31%. Patients continuing to take their
existing FS combination were on average 63% adherent;
however even in this group, only 48% exhibited adequate adher-
ence. The sub-analyses showed that patients who were new to
anti-asthmatic medications had the worst medication adherence
(59% for FSC; 8% for LABA+ICS). Patients with add on med-
ication (as a surrogate for severe asthma) showed a mean MPR
of 74% in the FSC and 39% in the LABA+ICS cohort. CON-
CLUSIONS: The use of the FSC combination was associated
with less treatment switching and less use of concomitant med-
ications. Furthermore the FSC cohort showed a better average
medication adherence and a higher proportion of adequate
adherent patients.
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OBJECTIVES: Population-based norms help in improving inter-
pretation of quality of life (QOL) data. The Esprint-15 ques-
tionnaire is a recently validated QoL questionnaire speciﬁc to
patients with allergic rhinitis (AR). This study was to obtain pop-
ulation reference norms for this new questionnaire. METHODS:
A cross-sectional study was carried out in primary care and spe-
cialized health care centers. The Esprint-15 questionnaire (which
has a global score and 4 dimension scores: symptoms, daily life
activities, sleep and psychological impact) was administered to a
large, heterogeneous sample of AR patients. The sample was
stratiﬁed on four characteristics (sex, age—three groups–, type
of AR—persistent and intermittent deﬁned as recommended in
the ARIA guidelines—, and symptom intensity—asymptomatic,
mild, moderate, severe). This classiﬁcation deﬁned 48 different
proﬁles of patients. Patient inclusion criteria were: over 18 years
old with a clinical diagnosis of AR, and visiting the doctor
because of AR at the time of inclusion in the study. RESULTS:
A total of 2682 AR patients were recruited: 53% women, 51%
with intermitent AR, and symptoms ranged from none or asymp-
tomatic (19%) to moderate (30%). Gender, type of AR and
symptom intensity but not age were associated with QOL scores
and were considered as stratifying variables for the reference
value tables. Mean overall score (standard deviation—SD) for
males was 2.18 (1.35) and for females 2.39 (1.37); mean (SD)
scores for patients with intermittent and persistent AR were 2.13
(1.35) and 2.47 (1.36), respectively. Reference values obtained
were organized in 29 tables, with values presented for each of
the three main variables individually and in combination via
means, standard deviations, medians, interquartile ranges and
decils. CONCLUSIONS: The reference values obtained in this
study will help to improve the interpretation of scores obtained
on the Esprint-15 questionnaire and should be useful in research
and clinical practice.
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OBJECTIVES: Ciclesonide is a novel inhaled corticosteroid (ICS)
for anti-inﬂammatory asthma therapy. Patients’ perception of
ICS-related side effects is not only important for treatment sat-
isfaction but might also have a major impact on compliance. We
used the new self-administered Inhaled Corticosteroid Ques-
tionnaire (ICQ) to compare patient-perceived side effects in a 
12-week, open-label, parallel-group study with ciclesonide or 
ﬂuticasone propionate (FP). METHODS: During the baseline
period (1–4 weeks), patients received either FP ≤ 250 μg/d (or
equivalent) or rescue medication only. Patients (n = 472, inten-
tion-to-treat population; 12–74 years) with FEV1 60–80% pre-
dicted (rescue medication) or ≥80% predicted (low dose ICS) and
deﬁned criteria for rescue medication use and asthma symptoms
were centrally randomized by IVR system to receive either 
320 μg ciclesonide once daily (ex-actuator, HFA-MDI), or 
200 μg FP twice daily (Diskus®). Patients completed the ICQ (57
questions, 7-point scale, 15 domains) at start and end of the
treatment. ICQ data were analysed by non-parametric methods
for differences between ciclesonide and FP. Intention-to-treat
analysis was of primary interest. RESULTS: After 12 weeks, the
ICQ overall score did not change signiﬁcantly in the ciclesonide
group (+0.22, p = 0.4200, two-sided), whereas statistically sig-
niﬁcantly increased (corresponding to patient-perceived worsen-
ing of the condition) in the FP group (+1.36, p = 0.0003,
two-sided). Similarly, there was no signiﬁcant change in the ICQ
domain scores in patients treated with ciclesonide, whereas with
FP signiﬁcant increases (p ≤ 0.0006, two-sided) occurred in the
domain scores “unpleasant taste” (+1.19) and “voice problems”
(+2.22). Ciclesonide was superior to FP regarding to changes in
ICQ overall score (point estimate −0.87, p = 0.0205, one-sided)
and domain score “voice problems” (point estimate −1.36, p =
0.0036, one-sided). CONCLUSION: ICS-related side-effects as
perceived by patients with moderate asthma worsened with the
relative low dose of FP 200 μg twice daily, but did not change
with ciclesonide 320 μg once daily after 12 weeks of treatment.
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OBJECTIVES: In order to measure the side effect perceptions of
patients using inhaled corticosteroids (ICS) the 57-item, 14-day
retrospective ICQ (15 domains and total score range: 0–100) was
developed. In this study we assessed the construct validity and
test-retest reliability of the ICQ in adult asthma patients.
METHODS: A total of 255 current inhaler users (non-ICS
inhaler n = 27; BDP equivalent daily low ICS dose ≤400 μg n =
61; mid dose ICS 401–800 μg n = 62; high dose ICS > 800 μg 
